Treatment of stress urinary incontinence using polyacrylamide hydrogel in women after radiotherapy: 1-year follow-up
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu klinické zkoušky kontrolované, časopisecké články, multicentrická studie, práce podpořená grantem
PubMed
26342812
DOI
10.1007/s00192-015-2834-2
PII: 10.1007/s00192-015-2834-2
Knihovny.cz E-zdroje
- Klíčová slova
- Pelvic radiotherapy, Polyacrylamide hydrogel, Stress urinary incontinence, Urethral bulking,
- MeSH
- akrylové pryskyřice aplikace a dávkování škodlivé účinky MeSH
- biokompatibilní materiály aplikace a dávkování škodlivé účinky MeSH
- dospělí MeSH
- hydrogely aplikace a dávkování škodlivé účinky MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory ženských pohlavních orgánů komplikace radioterapie MeSH
- prospektivní studie MeSH
- průzkumy a dotazníky MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- stresová inkontinence moči komplikace farmakoterapie patofyziologie MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky kontrolované MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- Názvy látek
- akrylové pryskyřice MeSH
- biokompatibilní materiály MeSH
- Bulkamid MeSH Prohlížeč
- hydrogely MeSH
- polyacrylamide MeSH Prohlížeč
INTRODUCTION AND HYPOTHESIS: Information on urethral bulking therapy in women after previous pelvic radiotherapy is lacking. This study compared the safety and efficacy of polyacrylamide intraurethral injections in patients with and without previous radiotherapy. METHODS: A total of 46 patients with severe stress urinary incontinence (SUI) were enrolled in this multicenter prospective trial. Group A consisted of 24 patients with previous radiotherapy to the pelvis for the treatment of a gynaecological malignancy. Group B consisted of 22 patients without previous radiotherapy. All patients were treated with a transurethral injection of a bulking solution (Bulkamid). The average follow-up was 12.4 months. The paired Wilcoxon test was used to compare the results before and after the procedure within the groups, and the two-sample Wilcoxon test was used for comparisons between groups. RESULTS: Complete continence was achieved in 25 % of patients in group A and in 36.4 % of patients in group B. Significantly reduced urine leakage was observed in both groups (p = 0.0164 in group A and p = 0.0002 in group B). The total scores in the International Consultation on Incontinence Questionnaire decreased by 5.2 in group A (p = 0.0000) and 6.36 in group B (p = 0.0001). The scores for the Total Patient Perception of Bladder Condition decreased by 1.54 in group A (p = 0.0001) and 2.59 in group B (p = 0.0000), with a significant difference between groups (p = 0.0224). No clinically significant changes in urodynamic parameters were observed. No severe adverse events were noted. CONCLUSIONS: Based on our results, we conclude that urethral bulking therapy is a valuable treatment option in patients with severe SUI who have undergone pelvic radiotherapy for the treatment of gynaecological malignancy.
Department of Obstetrics and Gynecology University Hospital Ostrava Czech Republic
Department of Surgical Studies Ostrava University Ostrava Czech Republic
Department of Urology University Hospital 17 listopadu 1790 Poruba 708 52 Ostrava Czech Republic
Zobrazit více v PubMed
Neurourol Urodyn. 2002;21(3):261-74 PubMed
Int Urogynecol J Pelvic Floor Dysfunct. 2009 Jun;20(6):619-21 PubMed
Neurourol Urodyn. 2004;23(4):322-30 PubMed
J Urol. 2014 Sep;192(3):843-9 PubMed
Eur J Obstet Gynecol Reprod Biol. 2014 Jul;178:199-202 PubMed
Int Braz J Urol. 2014 Jan-Feb;40(1):37-43 PubMed
Int Urogynecol J Pelvic Floor Dysfunct. 1997;8(1):18-24 PubMed
Int Urogynecol J. 2011 Mar;22(3):353-6 PubMed
Urology. 2009 Jan;73(1):11-3 PubMed
Int Urogynecol J Pelvic Floor Dysfunct. 2009 Feb;20(2):159-63 PubMed
Urology. 2013 Sep;82(3):713-7 PubMed
Onkologie. 2003 Aug;26(4):334-40 PubMed
Dermatol Surg. 2008 Jun;34 Suppl 1:S68-77; discussion S77 PubMed
Eur Urol. 2006 Jun;49(6):1079-86 PubMed
J Urol. 2009 Jan;181(1):204-10 PubMed
Int Urogynecol J. 2013 Feb;24(2):241-7 PubMed
Scand J Urol Nephrol. 2001 Dec;35(6):484-90 PubMed
Int Urogynecol J. 2012 Apr;23(4):429-33 PubMed
